|

CAPOX Clinical Trials

12 actively recruiting trials across 3 locations

No change since June 2026

Also known as: Active Comparator, Capecitabine + Oxaliplatine, Capecitabine and oxaliplatin, Capecitaine, Oxaliplatin, capecitabine, oxaliplatin

Pipeline

Phase 1: 1Phase 2: 4Phase 3: 3Phase 1/2: 1Phase 2/3: 2

Top Sponsors

  • Hebei Medical University Fourth Hospital2
  • Bristol-Myers Squibb2
  • The First Affiliated Hospital of Zhengzhou University1
  • Sun Yat-sen University1
  • Phanes Therapeutics1

Indications

  • Cancer12
  • Locally Advanced Rectal Cancer3
  • Colorectal Cancer2
  • pMMR (Microsatellite Stable Rectal Cancer)1
  • Ampullary Adenocarcinoma1

Other9 trials

Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)
Phase 2
Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer
Phase 3
PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
Phase 2
Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer
Phase 2
Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)
Phase 3
Preoperative Radiotherapy And ASTX660 in Rectum Cancer
Phase 1
Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）
Phase 2
TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer
Phase 3
The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer.

Phoenix, Arizona1 trial

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Local Institution - 0284

Phase 2/3

Tucson, Arizona1 trial

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Local Institution - 0428

Phase 2/3

Duarte, California1 trial

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.